Hancock Jaffe Laboratories, Inc. announced that it has appointed accomplished medical device professionals Dr. Francis Duhay and Dr. Sanjay Shrivastava, and recognized fund manager and equity analyst Marc W. Robins, CFA to its board of directors, effective as of October 2, 2018. Each of the new directors qualifies as independent under Nasdaq Stock Market rules. Mr. Robins will be Chairperson of the Audit Committee, Dr. Shrivastava will be the Chairperson of the Compensation Committee, and Dr. Duhay will be the Chairperson of the Nominating Committee, with each of the directors serving as independent directors of each of the committees. Robert Andersen, Robert Doyle, and Steven Girgenti resigned from the Board of Directors effective October 1, 2018. Drs. Duhay and Shrivastava and Mr. Robins will be appointed to fill the vacancies on the board by be reason of such resignations. The new directors will hold their positions until the next election of the class for which the director has been chosen. Dr. Duhay and Dr. Shrivastava are expected to be nominated for election as directors at the company's 2018 annual meeting of stockholders and Mr. Robins is expected to be nominated for election at the 2019 annual meeting. Following the new board appointments and resignations, the Hancock Jaffe board remains at five members, including the three new directors together with Yury Zhvillo, the company's Chairman of the Board, and Robert Berman, the company's Chief Executive Officer.